Stoke Therapeutics (STOK) Return on Sales (2022 - 2026)

Stoke Therapeutics' Return on Sales history runs 5 years deep, the most recent figure standing at 0.08% for Q1 2026.

• In Q1 2026, Return on Sales fell 9.0% year-over-year to 0.08%; the TTM figure through Mar 2026 stood at 0.05% (down 6.0% YoY), while the FY2025 annual figure was 0.0%, up 2.0% from the prior year.
• Return on Sales was 0.08% for Q1 2026 at Stoke Therapeutics, up from 0.41% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q1 2025 to a low of 0.41% in Q4 2025.
• Historically, Return on Sales has averaged 0.08% across 5 years, with a median of 0.07% in 2023.
• The sharpest annual moves came in 2024 and 2025: Return on Sales grew 9 bps in 2024, then sank 41 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.08% in 2022, then retreated by 23 bps to 0.1% in 2023, then surged by 95 bps to 0.0% in 2024, then sank by 8631 bps to 0.41% in 2025, then soared by 81 bps to 0.08% in 2026.
• The last three Return on Sales figures came in at 0.08% (Q1 2026), 0.41% (Q4 2025), and 0.04% (Q3 2025), per Business Quant data.